Cardioprotective role of carvedilol in patients on chemotherapy: systematic review and meta-analysis of randomized clinical trials
DOI:
https://doi.org/10.24265/horizmed.2018.v18n1.08Keywords:
Adrenergic beta-antagonists, Drug therapy, CardiotoxicityAbstract
Objective: Cancer therapy may cause cardiovascular toxicity even after successful treatment. It is unknown the cardioprotective role of carvedilol in this setting. We evaluated the role of carvedilol for the prevention of left ventricular systolic dysfunction in chemotherapy patients. Materials and methods: A systematic review and meta-analysis of randomized clinical trials were performed through PubMed, Embase, Cochrane, SciELO and ClinicalTrials.gov, including trials that evaluated and compared the difference of left ventricular ejection fraction (pre- and post-chemotherapy) in patients with and without carvedilol treatment. The effect size was expressed as the standardized difference (d) and the mean difference between groups with 95 % confidence interval. Results: Nine thousand seven hundred forty-nine (9,749) manuscripts were screened. Four (4) studies consisting of a total of 343 adult patients, from which 86.9 % were females with normal left ventricular ejection fraction and no past history of heart failure, were included. The carvedilol group showed less –though not statistically significant– reduction of the left ventricular ejection fraction than the control group (d = -0.501 [-1.372, 0.371]; p = 0.260). The difference of the reduction in the left ventricular ejection fraction pre- and post-chemotherapy in both groups was -0.71 % [-1.88, 0.46]. However, left ventricular ejection fraction post-chemotherapy was higher in the carvedilol group (d = 0.361 [0.146, 0.575]; p = 0.006) and the effect size was 1.73 % [0.74, 2.72]. Conclusions: Monotherapy or combination therapy with carvedilol is associated with a higher left ventricular ejection fraction, but not with less reduction in the left ventricular ejection fraction post-chemotherapy. Long-term, larger and high-quality randomized clinical trials are required to determine the clinical implication of the use of carvedilol in patients under chemotherapy.
Downloads
References
World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008. Disponible en: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri M, Goldhirsch A, Cipola C, Roila F. Cardiovascular toxicity by chemotherapy: targeted agents and radiotherapy: ESMO Clinical Pactice guidelines. Annals of Oncology. 2012; 23 (7):155-166. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22997448
Suter TM, Ewer MS. Cancer drugs and the heart: Importance and management. Eur Heart J. 2013;34(15):1102-1111. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22789916
Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16):1673-1684. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16236738
Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy.J Clin Oncol. 1993;11:1199–1203. Disponible en: http://ascopubs.org/doi/abs/10.1200/jco.1993.11.7.1199?journalCode=jco
Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). The Lancet. 1999;353(9169):2001-7. Disponible en: http://www.sciencedirect.com/science/article/pii/S0140673699044402
CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial. Lancet. 1999; 353(9146):9-13. Disponible en: http://www.sciencedirect.com/science/article/pii/S0140673698111819
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194-9. Disponible en: http://circ.ahajournals.org/content/106/17/2194.short
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349-55. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJM199605233342101#t=article
Australia/New Zealand Heart Failure Research Collaborative Group. Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349(9049):375.
Heidenreich P, Lee T, Massie B. Effect of beta blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. JACC 1997; 30(1):27-34. Disponible en: http://www.sciencedirect.com/science/article/pii/S0735109797001046
Wali R, Iyengar M, Beck G, Chartyan D, Chonchol M, Lukas M, Cooper C, Himmelfarb J, Weir M, Berl T, Henrich W, Cheung A. Efficacy and Safety of Carvedilol in Treatment of Heart Failure with Chronic Kidney Disease: A Meta-Analysis of Randomized Trials Circ Heart Fail. 2011;4:18-26.
Bovelli D, Plataniotis G,Roila F. Cardiotoxicity of therapeuthics agents and radiotherapy related heart disease;}: ESMO Clinical Practice Guidelines. Annals of Oncology 2010; 21(5):v277-82. Disponible en: https://academic.oup.com/announc/article21/suppl_5/v277/194029
El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on Adriamycin left-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail . 2012;18(8):607-13. Disponible en:http://www.sciencedirect.com/science/article/pii/S1071916412006124
Liu L, Liu Z, Liu Y, Zheng Z, Liang X, Han Y, et al. Preventive effect of low dose carvedilol combined with candesartan on the cardiotoxicity of anthracyline drugs in the adjuvant chemotherapy of breast cancer. Zhongua Zhong Liu Za Zhi. 2013;35(12):936-40. Disponible en: http://europepmc.org/abstract/med/24506965
Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy induced left ventricular systolic dysfunction in patients with malignant hemopathies. JACC. 2013;61(23):2355-62. Disponible en: http://www.sciencedirect.com/science/article/pii/S0735109713013983
Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. JACC. 2006;48(11):2258-62. Disponible en: http://www.onlinejacc.org/content/48/11/2258
Salehi R, Zamani B, Esfehani A, Ghafari S, Abasnezhad M, Goldust M. Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma. The Am Heart Hosp J. 2011;9(2):95-8. Disponible en: http://europepmc.org/abstract/med/24839645
Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiology journal. 2014;21(5):509-15. Disponible en: https://journals.viamedica.pl/cardiology_journal/article/view/35557
Beheshti AT, Toroghi HM, Hosseini G, Zarifian A, Shandiz FH, Fazlinezhad A. Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology. 2016;134(1):47-53. Disponible en: https://www.karger.com/Article/PDF/442722
Zhang SW, Zhang XX, Shi ZC, et al. Heart protective effect of carvedilol combined with trimetazidine on breast cancer patients receiving anthracycline. Chinese General Practice. 2016; (19)7:794-798
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and ExplanationsPRISMA Extension for Network Meta-analysis. Ann Intern Med. 2015;162(11):777-84.Disponible en: http://annals.org/aim/fullarticle/2299856/prisma-extension-statement-reporting-systematic-reviews-incorporating-network-meta-analyses
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19622511
Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010;121(5):675-83. Disponible en: http://europepmc.org/articles/pmc2834271
Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J. 2015;91(1081):627-33. Disponible en: http://pmj.bmj.com/content/91/1081/627.abstract
Manrique CR, Spinetto PV, Tiwari N, Romero J, Jorde U, Garcia M. Protective Effect of Beta-Blockers on Chemotherapy Induced Cardiomyopathy: a Meta-Analysis of Prospective Studies.(abstract) J Am Coll Cardiol. 2016; 67(13):1529. Disponible en: https://www.infona.pl/resource/bwmeta1.element.elsevier-c2e8492d-5b4e-3a41-9067-29e3f6ad91e1
Sellier P, Broustet J-P. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris. Am J Cardiovasc Drugs. 2003;3(5):361-9. Disponible en: https://link.springer.com/article/10.2165/00129784-200303050-00007
Kowalski J, Banach M, Barylski M, Irzmanski R, Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cellular & molecular biology letters. 2008;13(2):230. Disponible en: https://cmbl.biomedcentral.com/articles/10.2478/s11658-007-0049-3
Brottier L, Barat J, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J. 1990;11(3):207-12. Disponible en: https://academic.oup.com/eurheartj/article-abstract/11/3/207/400317
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle heart failure model. Circulation. 2006;113(11):1424-33.Disponible en: http://circ.ahajournals.org/content/113/11/1424.short
Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC, et al. Prevalence and prognostic significance of heart failure stages. Circulation. 2007;115(12):1563-70. Disponible en: http://circ.ahajournals.org/content/115/12/1563.short
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’than cancer? Five‐year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3(3):315-22. Disponible en: http://onlinelibrary.wiley.com/doi/10.1016/S1388-9842(00)00141-0/full
Machado V, Cabral A, Monteiro P, Goncalves L, Providencia L. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol. 2008;27(10):1277-96. Disponible en: http://europepmc.org/abstract/med/19178029
Brown J, Jenkins C, Marwick TH. Use of myocardial strain to assess global left ventricular function: a comparison with cardiac magnetic resonance and 3-dimensional echocardiography. Am Heart J. 2009;157(1):102-5. Disponible en: http://www.sciencedirect.com/science/article/pii/S000287030800820X
Feigenbaum H, Mastouri R, Sawada S. A practical approach to using strain echocardiography to evaluate the left ventricle. Circ J. 2012;76(7):1550-5. Disponible en: https://www.jstage.jst.go.jp/article/circj/76/7/76_CJ-12-0665/_article/-char/ja/
Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr. 2011;12(12):945-52. Disponible en: https://academic.oup.com/ehjcimaging/article/12/12/945/2396952
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
